Arthur Pearson, MD
Family Medicine · Poteau, OKNPI 1811331754
Payments from drug & device makers
Across 200 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$543
- Sanofi-aventis U.S. LLC$528
- Novo Nordisk$387
- Boehringer Ingelheim$267
- GSK$233
- Pfizer$147
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,20997%
- Education$853%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $543 |
| Sanofi-aventis U.S. LLC | 19 | $528 |
| Novo Nordisk | 27 | $387 |
| Boehringer Ingelheim | 17 | $267 |
| GSK | 14 | $233 |
| Pfizer | 10 | $147 |
| Lilly USA, LLC | 10 | $136 |
| AbbVie(2 entities) | 6 | $120 |
| Exact Sciences | 7 | $110 |
| Johnson & Johnson | 7 | $108 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $86 |
| Lundbeck LLC | 3 | $84 |
| Merck | 6 | $77 |
| Bayer | 4 | $71 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $40 |
| Sumitomo Pharma America, Inc. | 8 | $39 |
| Mylan Specialty L.p. | 2 | $39 |
| Amgen | 3 | $38 |
| Otsuka America Pharmaceutical, Inc. | 1 | $33 |
| Amarin Pharma, Inc. | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Viatris Specialty LLC | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOUJEO$119
How this compares
$3,293 in reported general payments places this provider in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 247 | $337,666 |
| EliquisApixaban | 586 | $277,953 |
| MounjaroTirzepatide | 171 | $252,440 |
| Tresiba Flextouch U-200Insulin Degludec | 190 | $210,017 |
| FarxigaDapagliflozin Propanediol | 208 | $203,414 |
| JardianceEmpagliflozin | 200 | $144,322 |
| TrulicityDulaglutide | 134 | $141,017 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 142 | $129,193 |
| XareltoRivaroxaban | 149 | $105,672 |
| AustedoDeutetrabenazine | 12 | $92,504 |
| GemtesaVibegron | 86 | $65,419 |
| LinzessLinaclotide | 45 | $48,680 |
| MyrbetriqMirabegron | 76 | $43,335 |
| Invega SustennaPaliperidone Palmitate | 11 | $40,414 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $40,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $136 | $393,457305 claims |
| Novo NordiskOzempic, Fiasp | $387 | $348,110278 claims |
| PfizerEliquis | $147 | $277,953586 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $543 | $242,770256 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $267 | $202,155285 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $233 | $150,417172 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $108 | $146,087160 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $39 | $65,41986 claims |
| AbbVieLinzess | $120 | $48,68045 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $43,33576 claims |
| NovartisEntresto | $14 | $36,39459 claims |
| MerckJanuvia, Belsomra | $77 | $34,49869 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Poteau
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.